Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Drug Updates: EULAR 2012

  |  Issue: August 2012  |  

Michele B. Kaufman, PharmD, BSc, RPh, is a freelance medical writer based in New York City and a Clinical Pharmacist at New York Downtown Hospital.

References

  1. Fleischmann R, Weinblatt M, Schiff M, et al. Abatacept SC versus adalimumab on background methotrexate in RA: One- year results from the AMPLE Study. Ann Rheum Dis. 2012;71:60.
  2. Weinblatt ME, Furst DE, Kavanaugh A, et al. Patient outcomes following 10 years of treatment with adalimumab in the DE020 roll-over trial. Ann Rheum Dis. 2012;71:665.
  3. de Vlam K, Lories RJ. Long-term TNF blockade induces joint repair in psoriatic arthritis. Ann Rheum Dis. 2012;71:109.
  4. Weinblatt ME, Bingham III CO, Mendelsohn AM, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with results observed by 2 weeks: Results of the phase 3, multicenter, double-blind, placebo-controlled trial. Ann Rheum Dis. 2012;71:368.
  5. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Ustekinumab in patients with active psoriatic arthritis: Results of the phase 3, multicenter, double-blind, placebo-controlled Psummit I study. Ann Rheum Dis. 2012;71:107.

Related Articles

    Do You Know Your Legal Obligations to Disabled Patients?

    The Americans with Disabilities Act (ADA) was passed in 1990 to protect the civil rights of people with disabilities. This law, and amendments passed in 2008, resulted in rules and regulations opening access to private settings serving the public, including doctors’ offices and medical facilities. The ADA includes a three-pronged definition of disability. If any…

    FDA Approves Ustekinumab for Children with PsA

    After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.

    How to Create a Safe Practice & Prep for a COVID-19 Resurgence

    For many months, the healthcare world has been significantly affected by the swift and per­vasive effects of SARS-CoV-2, which causes COVID-19. The virus has severely affected the delivery of patient care by all providers, including those in hospitals and emergency care settings, who grappled with the response to massive influxes of COVID-19 patients, and those…

    kenary820 / shutterstock.com

    Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…